

**PRESS RELEASE**

Lund, Sweden, November 10, 2021

## **Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®**

**Spago Nanomedical AB today announced it has signed an agreement with the global CRO Cmed Group Limited for the development of the first clinical study with the company's therapy project Tumorad.**

The aim of the clinical trial will be to assess safety and demonstrate proof-of-concept in cancer patients. The first preparatory phase, that is now in progress, includes the design of the clinical study protocol and compilation of material for the clinical trial application, consultation and advice with relevant regulatory agencies, and identification of suitable clinical sites for the study.

"The agreement with Cmed marks an important step in the preparations of the clinical development of Tumorad. The study design is emerging, and I look forward for us to initiate the first clinical trial with our candidate drug SN201 in cancer patients in 2022", said Mats Hansen, CEO of Spago Nanomedical.

"We look forward to contribute to the development of Tumorad, which is an exciting new product for the treatment of aggressive cancer", said Stephanie Langouet, COO of Cmed.

The regulatory preclinical dosimetry and toxicology studies with SN201 are progressing well and preparations for GMP production are ongoing with an external contract manufacturing organization.

---

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, [mats.hansen@spagonanomedical.se](mailto:mats.hansen@spagonanomedical.se)

**Spago Nanomedical AB** is a Swedish nanomedicines company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical's share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see [www.spagonanomedical.se](http://www.spagonanomedical.se). FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, [info@fnca.se](mailto:info@fnca.se).

**Cmed**, established for 20 years, is a global technology-led full services CRO specializing in complex disease areas, particularly oncology, immuno-oncology, cell therapy and other specialty therapeutics areas. Cmed has built a reputation for delivering these clinical trials with expertise, and a personalized, flexible approach, and a mission to contributing to the development of innovative medicines for the benefits of the patients. Cmed has a strong data management and statistics heritage. As well as being a Functional Service Provider of these services, via its Cmed Technology business (part of Cmed Group) Cmed has developed and uses an advanced, enterprise, cloud based clinical data system, **encapsia®**. **encapsia** delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics and AI. Client benefits include informed trial progress, deep insights into their data to support timely management decisions and particularly relevant with the disruption caused by the COVID-19 pandemic, able to support remote, decentralized and virtual trial conduct. Cmed is an Alten company and operates with ALTEN Clinical Group. For more information, visit [www.cmedresearch.com](http://www.cmedresearch.com) and [www.encapsia.com](http://www.encapsia.com) or contact [Info@cmedgroup.com](mailto:Info@cmedgroup.com).

---

**Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®**